Xtant Medical Announces Third Quarter 2025 Financial Results
Total Revenue of $33.3 Million Increased 19% Year-over-Year
Delivers Positive Net Income, Adjusted EBITDA, and Operating Cash Flow
Reiterates FY25 Revenue Guidance of $131-$135 Million, Representing Growth of 11%-15% over FY24
Sale of Certain Hardware Assets and International Businesses to Companion Spine Anticipated to Close by Year-End
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a global medical technology company specializing in surgical solutions for spinal and orthopedic conditions. The company recently shared its financial and operational highlights for the third quarter ended September 30, 2025.
Financial Highlights for Q3 2025
In the third quarter of 2025, Xtant Medical achieved impressive financial results:
- Revenue reached $33.3 million, a 19% increase compared to the same quarter last year.
- Gross margin improved to 66.1%, up from 58.4% year-over-year.
- Net income turned positive, totaling $1.3 million, a substantial recovery from a net loss of $5.0 million in the previous year.
- Adjusted EBITDA stood at $4.5 million, whereas an adjusted EBITDA loss of $1.0 million was reported previously.
- Cash generated from operations amounted to $4.6 million, contrasting with cash used in operations of $1.7 million from the prior year.
- The company confirmed its revenue guidance for FY25, expecting between $131 million and $135 million, reflecting an anticipated growth between 11% and 15% compared to the previous year.
Recent Business Strategies
Xtant Medical has also focused on strategic initiatives during Q3:
- The pending sale of its non-core Coflex® and CoFix® assets is expected to be finalized by year-end, allowing the company to concentrate on its core biologics business.
- Launched CollagenX™, a bovine collagen particulate product aimed at enhancing surgical wound closure and addressing concerns related to surgical site infections.
Sean Browne, President and CEO of Xtant Medical, commented, "Our strong third quarter results underscore our commitment to self-sustainability through improved free cash flow. We're optimistic that our new product launches and planned sales force investments will drive continued growth in our biologics revenue. The anticipated asset sale to Companion Spine will refocus our efforts on delivering innovative solutions that improve patient outcomes and create significant shareholder value."
Outlook for the Financial Year 2025
As of September 30, 2025, Xtant Medical confidently reiterated its revenue guidance of $131 to $135 million. This projection reflects a promising growth trajectory as the company pushes for innovation and customer satisfaction within the medical technology sector.
Furthermore, Xtant Medical's financial resilience is highlighted by its enhanced cash and cash equivalents, which increased to $10.6 million as of late September 2025, compared to $6.2 million at the close of December 2024.
Conference Call and Further Information
Xtant Medical will conduct a conference call to elaborate on these results at 8:30 AM ET. Interested parties can participate by calling the provided numbers. A replay of the call will be accessible via the Investor section of the company's website.
About Xtant Medical Holdings, Inc.
Xtant Medical is dedicated to respecting the value of organ donation, ensuring patients can experience full and enriched lives. The company focuses on designing, developing, and marketing a diverse array of orthobiologics targeting chronic and surgical wound care and sports medicine markets.
Frequently Asked Questions
What were Xtant Medical's key financial results for Q3 2025?
The company reported a revenue of $33.3 million, marking a 19% increase, along with a positive net income of $1.3 million.
What is the revenue guidance for FY2025?
Xtant Medical is reiterating its revenue guidance of $131 million to $135 million for the fiscal year, indicating a potential growth of 11%-15% over FY24.
What is the significance of the Companion Spine deal?
The anticipated sale of non-core assets to Companion Spine will sharpen Xtant's focus on its biologics business, aligning with their strategic goals for growth.
How is Xtant Medical addressing operational efficiency?
The company emphasized sustainable growth by improving cash flow and managing expenses while investing in new product lines and sales initiatives.
What innovative products has Xtant introduced recently?
Xtant Medical launched CollagenX™, designed to enhance surgical wound healing and minimize infection risks, reflecting its commitment to advancing surgical technology.
